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Summary
In this report we have approached two questions relating to the mechanism of action of cyclosporin
A (CsA) . First, we address whether the major cytosolic protein for CsA, cyclophilin, is directly
involved in mediating the immunosuppressive activity of this drug, and, in particular, whether
inhibition of this protein's peptidyl-prolyl cis-trans isomerase (PPIase) activity results in inhibition
of murine T cell activation. Second, we ask whether the nephrotoxicity observed with CsA
is related to inhibition of PPIase-dependent pathways in cells other than lymphocytes . Using
a series of 61 cyclosporin analogues, we generally found a good correlation between cyclophilin
binding and immunosuppressive activity for the majority ofanalogues analyzed. However, a number
ofcompounds of distinct structural classes were found that could interact with cyclophilin but
were much less immunosuppressive than expected . The inability of these analogues to inhibit
lymphocyte activation could not be explained by their failure to enter the cell and bind to cyclophilin
under the conditions used in the cellular assays . Surprisingly, a nonimmunosuppressive analogue,
McAla-6, whichbound well to cyclophilin and was active as a PPIase inhibitor, did not induce
renal pathology in vivo . Furthermore, another analogue, McBm2t, which was immunosup-
pressive in vitro, possessed little or no activity as a PPIase inhibitor. These findings pose serious
questions concerning a direct role of cyclosporin in mediating C&Ns immunosuppressive and
nephrotoxic activities . In addition, they raise doubts about whether PPIase has a direct function
in lymphocyte signal transduction .
C
yclosporin A (CsA)t has been widely used for over a
decade for the treatment of allograft rejection and graft-
vs.-host disease and is currently the treatment of choice for
these clinical conditions . Despite CSNs widespread utility,
patients treatedwith this immunosuppressive drug experience
significant side effects, including nephrotoxicity, hepatotox-
icity, CNS disturbances, hirsutism, and gingival hyperplasia
(reviewed in reference 1) . Nephrotoxicity, in particular, has
limited CsNs promising therapeutic effects in a number of
autoimmune disorders (1, 2). While it is clear that the dis-
covery of a safer analogue would greatly expand the clinical
'Abbreviations used in this paper. BUN, blood urea nitrogen ; CsA,
cyclosporinA ; FKBP, FK-506 binding protein ; PPIase, peptidyl-prolyl cis-
trans isomerase .
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utility of this powerful class of immunosuppressive agents,
a better understanding of the relationship between the mech-
anism(s) that cause immunosuppression and nephrotoxicity
are needed before such drugs can be developed in a rational
manner.
It is well established that CsA inhibits T cell activation
by blocking the transcription of a family of early activation
genes, including those of the principalT cell growth factors,
IL-2 and IIT4 (3-5). However, we and others have concluded
that CsA does not act directly at the transcriptional level,
but rather inhibits an earlier event in lymphocyte signal trans-
duction associated with activation pathways that cause a rise
intracellular calcium (6-10) .
A number of molecules have been proposed as the bio-
chemical site ofCsNs action in these events. Cyclophilin, dis-
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tous and abundant cytosolic protein that is highly conserved
among eukaryotic organisms, and is responsible for the up-
take of CsA into the cell . Several observations support the
hypothesis that cyclophilin is involved in CsNs mechanism
ofaction. First, the specificity ofcyclophilin binding has been
examined with a limited set ofcyclosporin analogs, and, with
this narrow series, immunosuppressive activity was found to
correlate with cyclophilin binding (12) . Second, cyclophilin
was recently discovered to catalyze the cis-trans isomerization
of peptidyl proline bonds (13, 14) . The ability ofCsA to in-
hibit this enzymatic activity could, in theory, interfere with
lymphocyte activation by hindering conformational changes
in transcriptional factors, protein kinases, or ion channels .
The discovery that the Drosophila ninaA mutant, which is
defective in the conversion of opsin to rhodopsin, has a mu-
tation in a cyclophilin-like gene (15, 16) illustrates how this
molecule may be involved in a signal transduction pathway.
Recently, Tropschug et al . (17) hasshown that yeast and Neu-
rospora that have been selected for CsA resistance possess
defects in their cyclophilin genes. Further support for the in-
volvement of cyclophilin in CsA!s action has come from the
unexpected discovery that the major cytosolic binding pro-
tein for the immunosuppressant FK-506, FKBP, has a similar
enzymatic activity (18, 19) . These correlative observations
suggest a critical role for cyclophilin in the mechanism of
action of CsA, but in mammalian cells no biochemical or
genetic data exist to provide a direct link . Thus, although
it is clear that cyclophilin is a major cytosolic receptor for
CsA and is responsible for the accumulation of thecompound
within the cell, the question of whether cyclophilin is the
mediator of CsKs immunosuppressive and/or nephrotoxic
activities has not been clearly resolved .
In this report we have taken a pharmacologic approach to
address this question . We have compared cyclophilin binding,
in vitro and in vivo immunosuppressive activity, peptidyl-
prolyl cis-trans isomerase (PPIase) activity, and in vivo neph-
rotoxicity for a more extensive and structurally diverse set
of cyclosporin analogues than previously investigated . 61 com-
pounds were prepared, including substitution at the various
amino acid residues of the peptide cycle and sidechain modi-
fications of the unique amino acid residue at position 1. Pre-
liminary reports with some of these compounds have previ-
ously appeared (20) . Overall, we found a good correlation
between cyclophilin binding and immunosuppressive activity
for the majority of analogues analyzed . On the other hand,
a number of compounds of distinct structural classes were
found that could interact with cyclophilin but were much
less immunosuppressive than expected . The inability of these
analogues to inhibit lymphocyte activation could not be ex-
plained by their failure to enter the cell and bind to cyclophilin
under the conditions used in the cellular assays . Surprisingly,
the nonimmunosuppressive analogue McAla-6, which bound
well to cyclophilin, was active as a PPIase inhibitor, but did
not induce renal pathology in vivo. Furthermore, another
analog, McBm2t, that was immunosuppressive in vitro,
bound weakly to cyclophilin and possessed little activity as
a PPIase inhibitor. These findings pose serious questions con-
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cerning a direct role of cyclophilin in mediating CSNs im-
munosuppressive and nephrotoxic activities. In addition, they
raise doubts about whether PPIase has a direct function in
lymphocyte signal transduction.
Materials and Methods
CsA Analogues.
￿
['H]dihydro cyclosporin was made by catalytic
reduction of the McBmt double bond in CsA with tritium gas
byNew England Nuclear (Boston, MA) using conditions andCsA
supplied by our laboratories.
The cyclosporin analogues included in this study were obtained
either by totally synthetic methods or semi-synthetic modification
ofCsA . Crystalline CsA was isolated from Sandimmune Oral So-
lution by flash chromatography on silica gel using dichloromethane-
methanol mixtures to elute CsA . Fractions containingUVlight-
positive material were combined and evaporated . Crystallization
was affected with acetone-hexane (92% recovery) . The totally syn-
thetic analogues were prepared via cyclization of the appropriate
unprotected linear undecapeptide using the mixed phosphonic an-
hydride method (21), essentially as described by Wenger (22) . The
precursor tetrapeptide and heptapeptide fragments were derived
using a combination ofthe mixedpivalic anhydride method modified
for N-methylated amino acid derivatives (23) and the BOP-CI
method (24, 25) . Where applicable, use of the BOP-Cl coupling
reagent afforded higher yields under more moderate conditions in
shorter reaction times. Coupling of the partially protected tetrapep-
tide with the McBmt-linked heptapeptide was effected using the
Castro (BOP) reagent (22) . The synthesis of McBm2t cyclosporin
has been published (26) .
McBmt was synthesized by modification of the Wenger proce-
dure (27) starting from (RR)-(+)-diethyl tartrate and resulting
in improvement in the overall yield from 6 to8%. The fluorinated
amino acids employed in the total synthesis ofanalogues containing
a fluoro-substituted amino acid residue at the 2, 5, or 11 positions
were provided by Dr. J . Kollonitsch andMr. L . Perrkins ofthe Merck,
Sharp and Dohme Research Laboratories, Basic Chemistry Dept .
Structural assignments were made with the aid ofhigh-field proton
and carbon-13 NMR spectroscopy and fast atom bombardment
(FAB) mass spectroscopy . Preparative details, along with charac-
terization data, will be reported elsewhere .
Proliferation Assays.
￿
Mouse splenicT cells were isolatedby nylon
wool column separation, washed twice, and resuspended at 10 6
cells/ml in culture medium made up ofRPMI 1640 (Gibco Labora-
tories, Grand Island, NY) containing 10% heat-inactivated FCS
(Flow Laboratories, McLean, VA), 2 mM glutamine, 1 mM so-
dium pyruvate, 2 x 10-5M 2-ME, and 50 Kg/ml gentamycin .
Cell suspensions were seeded (100 pl/well) into flat-bottomed 96-
well microplates (Costar, Cambridge, MA) . Various dilutions of
the compound under test, in parallel with a standard range ofCsA
concentrations, were added to the wells in triplicates and the cul-
tures received a mixture of ionomycin (250 ng/ml) and PMA (10
ng/ml) . Cultures were incubated for 48 h at 37°C in a humidified
atmosphere of5% COZ-95% air and pulsed with PH]TdR (2 p,Ci/
well) for the last 4 h . Cells were harvested on fiber glass filters
and the incorporated radioactivity was measured in a Betaplate liquid
scintillation spectrometer (PharmaciaLKB Biotechnology, Inc., Pis-
cataway, NJ) .
In the experiments to test for antagonist activity ofC&A ana-
logues, the cells first received various concentrations of McAla-6
and were incubated for 3 h at 37°C . Various concentrations of CsA
were then added and the cultures activatedwith ionomycin + PMA,
as described above.Cyclophilin Binding Assays.
￿
Cyclophilin was purified from calf
thymus according to Harding et al . (28) . In all experiments de-
scribed, binding assays were performed with the major (pl 8.6)
species of cyclophilin ; analogues that showed a discrepancy between
immunosuppression andbinding to the major isoformwere assayed
against the minor (pl 6.8) species of cyclophilin . No differences
between the two isoforms were observed (data not shown) . A
modification of the LH-20 binding assay described by Hand-
schumacher et al . (11) was used for competitive binding studies.
Compounds were dissolved in ethanol and diluted in 20 mM so-
dium phosphate + 0.1% Tween-80, pH 7.2, in 100 Al . 50 AI of
cyclophilin at 10-20 ug/ml was added + 50 Al of [3H]dihydro cy-
closporin (0.6 ug/ml at 4 p,Ci/Rg) . After mixing, bound [3H]di-
hydro cyclosporin was separated from free by passing over a 2-ml
micro-column of LH-20 (Pharmacia Fine Chemicals, Piscataway,
NJ) . Thecolumn was eluted with 500 Al of 20 mM sodium phos-
phate and the void volume counted in Aquasol (Dupont, Boston,
MA) in aBeckman Instruments, Inc . (Palo Alto, CA)LS 9000 scin-
tillation counter.
The binding results are reported as the IC5o of percent inhibi-
tion of binding, calculated as follows : 100 x [100 - (cpm .of com-
petitor - cpm of nonspecific binding)/(cpm of maximal bound
- cpm of nonspecific binding)].
Nonspecific binding was determined by binding to cyclophilin
in the presence of excess CsA (50 ug/ml) . Determinations were
made in duplicate and the ICso's calculated by linear regression on
6-8 doubling dilutions of competitor. Analogues were compared
to a CsA standard which was run in each experiment .
Competitive whole cellbinding assays wereperformed as follows.
SplenicT cells suspended in RPMI 1640 containing2% FCSwere
aliquoted at 106 cells/sample in a final volume of 300 Al to which
were added 8 nM [3H]dihydro cyclosporin (150 x 103 cpm) and
various concentrations ofcold competitor.Thesampleswere mixed
vigorously and incubated for 30 min at 37°C. Cells were then
washed once with ice-cold RPMI, spun, resuspended in 100 Al
medium, and overlayed on a 10% sucrose solution in Eppendorf
microcentrifuge tubes. The tubes were spun at 8,000rpm for 1 min,
frozen, and the tips containing the cell pellets were cut out and
counted for incorporated radioactivity .
Proline Isomerase Assays.
￿
Cyclophilin PPIase activity was assayed
as previously described (14, 18) except that the cyclophilin used
(at 3.3 Ag/ml) was partially purified through the Matrix Blue A
affinity chromatography step (28) . Briefly, the PPIase assay used
measures the cis to trans isomerization of the proline-alanine pep-
tide bond in the peptide, N-succinyl-Ala-Ala-Pro-Phep-nitroanfide.
Under equilibrium conditions, -88% of the peptide is present as
the turns form and is readily cleaved by chymotrypsin.Theremaining
12% of the peptide present in the cis form is cleaved upon enzy-
matic conversion to the trans form. The size ofconversion wasmoni-
tored by the change in absorbance at 405 nm due to the release
ofp-nitroaniline. Data points were fit to a simple first-order rate
law and the rate constant, k, was determined . K ; values for the
inhibition of cyclophilin PPIase activity byC&Aand other analogs
were determined from the dependence of the first order rate con-
stant, k, on inhibitor concentration using the equation of Wil-
liams andMorrison (29) for tight-binding inhibition. Acomputer
program, writtenby NancyThornberry of theDepartment ofEn-
zymology, Merck, Sharp andDohme Research Laboratories, was
used for this purpose.
Nephrotoxicity Assays.
￿
8-12-wk-old BALB/cJ female mice (The
Jackson Laboratory, Bar Harbor, ME) were used . Stock solutions
ofCsA and analogues were made up at 50 mg/ml in 33% eth-
anol/67% cremophor (BASF, Parsippany, NJ) . Further dilutions
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were made in saline . Assessment of the nephrotoxic potential of
the compounds was done with two different treatment protocols .
In the first protocol, referred to as chronic nephrotoxicity assay,
the mice received seven daily intraperitoneal injections of various
doses of compound or of vehicle alone. Serum, kidney, and liver
were collected 24 h after the last injection . In thesecond protocol,
mice were given high doses of compound intraperitoneally for 2
consecutive d, and serum, kidney, and liver were taken 48h later.
Measurement of blood urea nitrogen (BUN) levels in the serum
was done on an autoanalyzer (model 203; Gilford Instrument
Laboratories, Inc ., Oberlin, OH). Histopathologic evaluation of
kidney and liver samples was done after standard fixation, sec-
tioning and staining procedures by Dr. Srinivasa Prahalada, Merck,
SharpandDohme Research Laboratories Safety Assessment (West
Point, PA) .
Delayed Hypersensitivity Response.
￿
CBA/Jfemalemicewere pur-
chased from TheJackson Laboratory (Bar Harbor, ME). Allmice
were housed in a sterile, pathogen-free environment and were at
least 10-12wk ofage before immunization .Mice were immunized
intravenously with 5 x 101 SRBC (Colorado Serum Co., Denver,
CO) in 0.5 ml of Dulbecco's PBS (Gibco Laboratories, Grand Is-
land, NY). 72 h after sensitization, mice were challenged by sub-
plantar injection in thehind foot with 5 x 101 SRBC in0.05 ml
of PBS . The magnitude of the delayed hypersensitivity response
wasmeasured 24 h later with a mercury plethysmograph and the
data expressed as Al of footpad swelling. CsA and analogs were
administered intravenously beginning with the day of immuniza-
tion and ending on the day of challenge for a total of four daily
doses. All compounds were dissolved in ethanol, diluted in
cremophor and then into PBS. The ED so for CsA in this assay is
ti7 mg/kg.
Results
Correlation between Cyclophilin Binding and Immunosuppres-
sive Activity. Atotalof61 cyclosporin analogswere prepared
either by totally syntheticmethods or semisynthetic modifica-
tion o£CsA. Close to halfof these modifications were made
in theMcBmtside chain, an aminoacid that is uniquely found
in CsA and that has previously been implicated in the im-
munosuppressive activity of the cyclosporins (12) . The re-
mainder of the analogues represent modifications at all the
other amino acids within the cyclic structure, with partic-
ular emphasis on the 2 position and the 6 position (6 and
7 analogues, respectively) .
In Fig. 1 we compare the immunosuppressive activity of
these 61 analogues with their ability to compete with [3H]di-
hydro cyclosporin for binding to cyclophilin . Immunosup-
pressive activity was assessed by three different methods: (a)
inhibition of IIr2 production by theT cell hybridoma FS.6 ;
(b) inhibition of a proliferative response induced in a murine
mixed lymphocyte response ; and (c) inhibition of murine T
cell proliferation stimulated by PMA + ionomycin. Since
each of these assays give virtually identical results (RZ's, be-
tween0.89and0.93),only thePMA + ionomycin assay results
are presented and discussed.
The majority ofCsAanalogues analyzed show good agree-
ment between cyclophilin binding and immunosuppressive
activity, as illustrated in Fig. 1 and summarized in Table 1.
However, for 14 compounds, this correlation does not hold;< 0.1
￿
1
￿
io
￿
100
cyclophilin binding (CsA=100)
Figure 1. Correlation plot comparing cyclophilin binding and im-
munosuppressive activities for61 cyclosporin analogues. All analogues were
testedfor inhibitory activity inaPMA + ionomycin-inducedT cell prolifer-
ation assay and for their ability to compete for [3H]dihydro cyclosporin
binding to purified calf thymus cyclophilin, with CsA run as a control
in each experiment . Results are plotted as the compound's activity relative
to CsA . Analogues showing agreement between the two assays (i .e.,
< five-fold difference between cyclophilin binding and immunosuppres-
sion) are plotted as open squares (0) . Other classes of compounds are
depicted as follows : McBm2t cyclosporin, (*); analogues substituted in
the 6-position, (/) ; analogues substituted in the 8 position, (A) ; and
Bmt derivatives in which the double bond has been eliminated and, in
most cases, a sulfur substitution has been made, (0) .
these are depicted by solid symbols in Fig . 1 . One analogue,
McBm2t cyclosporin, (designated as class III in Table 1 and
whose structure is given in Fig. 2), retains immunosuppres-
sive activity but does not compete for [3H]dihydro cyclo-
sporin in the cyclophilin binding assay.
Compounds that retain significant cyclophilin while losing
immunosuppressive activity (designated class IV in Table 1)
fall into three distinct structural classes . Five of the class IV
analogues are modified at the 6 position. Detailed informa-
tion for this class ofcompounds is listed in Table 2 and repre-
sented by the McAla-6 derivative in Fig. 2 . Two other 6 posi-
tion analogues, McNval-6 and McPhe-6, do not show the
discrepancy between cyclophilin binding and cell biological
readouts. It should be noted that extensive modifications at
other positions in the cyclosporin ring, such as at the 2 posi-
tion, or substitution of alanine at other positions in the ring
structure, do not generate compounds that fall into class IV,
Table 1 .
￿
Summary of the Correlation Between Cyclophilin
Binding and Immunosuppressive Activity
Table 2 .
￿
Structure Activity Relationships Among Selected
Cyclosporin Analogues
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Analogues are designated as showing agreement between thetwo as-
says (Class I or II) if they show less than a five fold difference between
￿
' Cyclophilin competitive binding assay.
cyclophilin binding and immunosuppression .
￿
t PMA+ionomycin-induced murine T cell proliferation assay .
Cyclophilin
binding
(percent of
CsA)`
In vitro
immunosuppressive
activity
(percent of CsA)t
6-position analogues
CH2CH(CH3)2 [CsA] 100 100
CH3 [MeAla-6] 51 0.4
CH(CH3)2 5 0.2
CH 2CH3 78 7
CH2CH2CH 3 43 45.8
CH(CH3)CH2CH 3 5 1
CH 2-Phenyl 31 11
CH3 , dihydro McBmt 10 <0.1
2-position analogues
CH2CH3 [CsA] 100 100
CH2CH 2CH3 [CsG] 23 45
CH2SCH3 2.5 5
CH2S(O)CH3 <0.1 <0.1
CH2CHF2 26 50
CH2CH 2F 12 8
CH 2CH2CH2F 2 2
Alanine ring substitutions
v-McAla-3 82 61
McAla-4 6 .5 2.5
Ala-5 10 .5 14
McAla-9 7.3 10
McAla-10 3.5 7 .5
McAla-11 8.5 15
Selected McBmt modified analogues
CH(OH)CH(CH3)CH2
CH=CH(CH3) [CsA] 100 100
CH(OH)CH(CH3)CH2
SCH3 [MeThia-Bmt] 178 9.5
CH(OH)CH(CH3)
CH2S(O)CH3 2.7 <0.1
CH(OH)CH(CH3)
CH,S(02)CH3 4 <0.1
CH(OH)CH(CH3)
CH2CH2SCH3 12 <0 .1
CH(OH)CH(CH3)
CH2S-Phenyl 18 18
CH(OH)CH(CH3)
CH2000H 3 <0.1
CH(OH)CH(CH3)
CH2CH 20H 16 <0.1
Class
Cyclophilin
binding Immunosuppression
No . of
compounds
I + + 37
II - - 10
III - + 1
IV + - 13Hap, ~CHs
,,~/ HaC - CH
￿
,~~C
~H9 N
CSA ,yc~0
.
f
. .
~Q
.
O H 100
McAla-6
McThia-Bmt
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Cycl philin
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￿
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asshown in Table 2 . Four of the class IV analogs areMcBmt
derivatives in which the double bond has been replaced with
a sulfur (see Table 2 and example in Fig. 2) . All but one sulfur-
substituted McBmt derivative fall into class IV, whereas 20
of 22 other McBmt modifications fall into either class I or
class II . Two analogues substituted at position 8 also fall into
class IV It is evident from this analysis that dissociation of
cyclophilin binding and immunosuppression is a property of
a distinct set of structural changes within the cyclosporin
molecule .
Analysis ofClass III and IV Compounds.
￿
The significant
number of CSA analogues of distinct structural classes that
show a discrepancy between cyclophilin binding and im-
munosuppressive activity calls into question the hypothesis
that cyclophilin is the biochemical mediator of this agent's
biological action . Therefore, we investigated whether com-
pounds that fell into class III or class IV behave differently
in culture than they do in the cell-free ryclophilin binding
assay. For example, one reason for a class IV compound to
behave in such a manner may be because it is degraded in
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Relative Activity (% of CsA)
PPlase Immuno-
Inhibition suppression
100 100
66
￿
0.4
135
￿
9.5
ND
￿
1 .0
Figure 2 .
￿
Structures of CsA and represen-
tative cyclosporin analogues. Data showing the
relative activity of these analogues in the cy
0.68
￿
35
￿
clophilin column binding assay, the PNU +
ionomycin T cell proliferation assay and ry-
clophilin peptidyl-prolyl cis-trans isomerase
(PPlase) assay are also listed in the figure.
cell culture or, in some other way, fails to enter the cell and
bind to ryclophilin . To address this possibility, we established
a whole cell competitive binding assay in which acompound
competes with [3H]dihydro cyclosporin for uptake into the
lymphocytes used in the biological assay. Merker and Hand-
schumacher (30) previously showed that cellular uptake of
CsA at 370C is due to its interaction with cytosolic ryclophilin .
In these experiments, we have focused the majority of our
attention on the McAla-6 analogue (Fig. 2), since it has a
large differential between ryclophilin binding (50-70% of
CsA) and immunosuppressive activity (0.4% of CsA) and
the single class III analogue McBm2t .
The results of a representative whole cell competitive
binding assay with CsA, McAla-6 and McBm2t are shown
in Fig . 3 . The experiment illustrates that McAla-6 competes
with [3H]dihydro cyclosporin uptake almost as well as does
CsA . Similar curves are obtainedwhen the competition assay
is carried out for 4 h rather than the 1-h incubation shown
in Fig. 3 (data not shown) . Therefore, since CsA must act
within the first few hours after T cell activation (31), thec
0
L
c
r
c
m
i
Figure 3.
￿
Effect of cyclosporin analogues on the binding of [3H]di-
hydrocyclosporin to murineT cells. Purified murine T cells were incubated
at 37°C with 8 nM (150 x 103 cpm) of [3H]dihydro cyclosporin, along
with increasing concentrations of CsA ("), McAla-6 (/), or McBm2t
("). After 60 min, the cells were centrifuged through a layer of 10%
sucrose to separate free fromcell-boundradioligand and the pellet counted.
Data are expressedas the percent inhibition ofthe control specific binding
(85% of total bound radioactivity), determined after subtraction of the
radioactivity incorporated in the presence of 2.5 g,M CsA.
lack of immunosuppressive activity is not due to degrada-
tion or failure to cross the plasma membrane. Indeed, all four
class IV compounds that had been determined to bind to cy-
clophilin in the more conventional biochemical assays were
also found to compete in the cellular assay, including one
of the sulfur-substituted McBmt analogues, McThia-Bmt (Fig.
Figure 4.
￿
Effect of McAla-6 on the immunosuppressive activity of CsA.
Various concentrations of McAla-6 or media were added to cultures of
murine T cells and incubated for 3 h at 37°C. CsA was then added and
the cultures activated with ionomycin + PMA. Final cultures contained
CsA alone ("), McAla-6 alone (A), or various concentrations of C&A
along with McAla-6 at the following concentrations: 25 nM (p); 100
nM (x); 400 nM (O); 1666 nM (A). Data are represented as the percent
inhibition of the control proliferative response.
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2) . McBm2t was a relatively ineffective competitor in this
assay, consistent with the results from the cell-free competi-
tive binding assay. These data further suggest that McBm2t
immunosuppressive activity is not due to unexpected trans-
port or concentration within the cell.
Ifcyclophilin is the mediator ofC&A's immunosuppressive
activity, then we would'predict that McAla-6 should block
the biological effects of CsA, since it can enter the cell and
displace [3H]dihydro cyclosporin's binding to cyclophilin.
Rapamycin, a compound structurally similar to the im-
munosuppressant FK-506, has been recently shown to block
uptake of ['H]dihydro FK-506 and act as a biological an-
tagonist of FK-506 (32). In order to test whether McAla-6
could antagonizeCsA in a similar manner, McAla-6, at con-
centrations ranging from 25 to 1,666 nM, was added to mu-
rine lymphocytes either alone or in combination with CsA,
and the lymphocytes stimulated with PMA + ionomycin.
The results of a representative experiment, shown in Fig. 4,
demonstrate that McAla-6 had no effect on the immunosup-
pressive activity of CsA. The concentration of CsA needed
to inhibit 50% of the proliferative response is 21 nM in the
control culture and range from 11 to 24 nM in the cultures
to which McAla-6 was added. Additional experiments in
which cells were preincubated with McAla-6 for shorter in-
tervals before addition ofCsA or in which alternative readouts
(e.g., 1172 production) or cell populations were employed also
failed to demonstrate that McAla-6 could act as a biological
antagonist ofCsA (data not shown). It should also be pointed
out that at the highest concentration used in these experi-
ments, McAla-6 is present at an 80-fold excess over the con-
centration of CsA needed for 50% inhibition, a ratiosufficient
to inhibit CsNs binding by 99%.
PPIase Inhibitory Activity ofCyclosporin Analogues.
￿
The ex-
periments in the preceding section raise questions about the
physiologic role of cyclophilin with respect to its involve-
ment in mediating the immunosuppressive effects of CsA.
Perhaps class IV compounds, such as McAla-6, bind to cy-
clophilin in a manner that does not inhibit the subsequent
biochemical steps in which the protein is involved. Since cy-
clophilin has been shown to have PPIase activity (13, 14),
we next asked whether immunosuppressive activity corre-
lates better with inhibition of enzyme activity than it does
with binding. Therefore, selected CsA analogues were as-
sayed for their ability to inhibit cyclophilin's PPIase activity,
and the results are shown in Fig. 5. McAla-6 is comparable
to CsA as a PPIase inhibitor, whereas McBm2t is a very
weak PPIase inhibitor. McThia-Bmt was somewhat more ac-
tive than CsA and McLeu-11 was inactive. The data clearly
show that analogues that can effectively compete with
[3H]dihydro cyclosporin for binding to cyclophilin can in-
hibit its PPIase activity, irrespective of the compound's im-
munosuppressiveactivity. In particular, McAla-6, which lacks
appreciable immunosuppressive activity, inhibits cyclophilin's
PPIase activity, while McBm2t is an effective immunosup-
pressant but is a poor PPIase inhibitor. Thus, for certain
structural classes of analogues, binding to cyclophilin and in-
hibition of PPIase activity are not sufficient to confer im-
munosuppressive activity.a
1 .0
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Figure 5.
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Effects ofvariouscyclosporin analogues on cyclophilin peptidyl-
prolyl cis-trans isomerase activity. Cyclosporin analogues (1 mg/ml stock
solutions in ethanol) were added to the standard PPIase assay (see Materials
and Methods) at the concentrations indicated and the rate of isomeriza-
tion calculated. The data are presented as Kinhib/Kcontrot, where Kcontrol is
the observed rate constant in the presence of enzyme and in the absence
of inhibitor and Ki n hib is the observed rate constant in the presence of en-
zyme and inhibitor.
Nephrotoxicity ofCyclosporin Analogues.
￿
CsA causes alter-
ations in renal function in a number of experimental animal
models, and nephrotoxicity is one of the principal clinical
side effects of this drug (1) . The most immediate effects of
CsA are on renal blood flow (33, 34) . Theories put forward
to explain thisphenomenon include induction ofthromboxane
(35, 36) or inhibition of prostacyclin release (37) from en-
dothelial cells, a direct effect on vascular smooth muscle con-
tractility (38, 39), an effect of the drug on neurotransmitter
release (40), and inhibition ofrenal microsomal protein chain
elongation (41) . Using theCsA analogues that differ in their
biochemical and immunosuppressive properties, we have
chosen to address a different set of questions in this study.
First, is the nephrotoxicity of CsA due to its ability to in-
hibit signal transduction pathways in cell types other than
the lymphocyte? Second, does the nephrotoxic potential of
a compound correlate with its immunosuppressive activity,
with its PPIase inhibitory activity or with some structural
feature of the cyclosporin molecule unrelated to these mech-
anisms?
Three in vivo assays were established to resolve these ques-
tions . To determine whether analogues were immunosup-
pressive in vivo,we assayed selected compounds for their ability
to inhibit a delayed hypersensitivity response, andwe obtained
good agreement between the in vitro and in vivo assays, as
shown in Table 3 . Next, two assays of nephrotoxicity were
established . In the first assay, BALB/c mice were given two
intraperitoneal doses of CsA or analogue (50-400 mg/kg)
at 24-h intervals; 24 h after the second dose, BUN levels were
measured and the kidneys removed for histopathology. Some
deaths were recorded in mice treated with 200 mg/kg CsA,
and there was modest elevation (30%) ofBUN at 100mg/kg
CsA. Mcroscopic examination ofthe kidneys in animals treated
with 200mg/kg ofCsA revealed evidence of diffuse tubular
degeneration characterized by cytoplasmic swelling and vacuo-
lation and dilation of tubular lumina, similar to previous
reports of CsA renal histopathology (42) . The renal mor-
phology was unremarkable at 100 mg/kg CsA . In the second
nephrotoxicity assay, BALB/c mice were treated, by intra-
peritoneal route, for 7 d with 50-200 mg/kg ofcompound
and killed on day 8 for histology and serum chemistries. While
there was little evidence of histopathologic change in mice
treated with 50mg/kg CsA, BUN elevation twofold above
control levels was typically observed .
Both assays were performed on the compounds listed in
Table 3 . For each analogue listed, the severity of nephrotox-
icity was equivalent in both assays . The level of renal dys-
function is based on the concentration required to induce his-
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' Cyclophilin competitive binding assay .
I PMA + ionomycin-induced murine T cell proliferation assay .
S Murine sheep red blood cell-specific delayed hypersensitivity response .
II Induction of nephrotoxicity, as measured in the 2- and 7-d assays described in Materials and Methods . Relative scoring of nephrotoxicity in the
2-d assay was as follows : + + +, pathologic changes at 200 mg/kg; + +, pathologic changes at 400 mg/kg ; +, mild pathologic changes at 400
mg/kg ; -, no pathologic changes at 400 mg/kg . Relative scoring of nephrotoxicity in the 7-d assay was as follows : + + + , BUN elevation at
50 mg/kg ; + +, BUN elevation at 100 mg/kg ; +, BUN elevation at 200 mg/kg; -, no BUN elevation at 200 mg/kg .
Table 3 . Ability
Name
of Cyclosporin Analogues to
!Cyclophilin binding
(percent of CsA)'
Induce Nephrotoxicity In Vivo
In vitro
immunosuppressive
activity (percent of CsA)t
Correlates with their Immunosuppressive
In vivo
immunosuppressive
activity (percent of CsA)S
Activity
Nephrotoxicityll
CsA 100 100 100 +++
CsG 23 45 50 +++
dihydro 36 38 33 +
McThia-Bmt 178 9.5 23 -
McAla-6 51 0.4 <10 -
McLeu-11 <0.1 <0.1 ND -topathologic changes in the 2-d assay and significant BUN
elevation in the 7-d assay. The highest concentrations ofdrugs
tested were 400 mg/kg in the 2-d assay and 200 mg/kg in
the 7-d assay. These restrictions were imposed by constraints
of compound availability and solubility .
The three immunosuppressive analogs listed in Table 3,
CsA, CsG, and dihydro cyclosporin, induce significant
nephrotoxicity in these experimental models, whereas the
nonimmunosuppressive compounds, McAla-6 and McLeu-11,
are not nephrotoxic. Another class IV compound, McThia-
Bmt, which binds well to cyclophilin but is only weakly im-
munosuppressive, does not induce renal pathology . This ana-
logue may have failed to induce renal pathology because the
nephrotoxicity assay may not have sufficient sensitivity to pick
up such a weakly activecompound . Nevertheless, the results
in Table 3 demonstrate that immunosuppressive activity, and
not ryclophilin binding or PPIase inhibitory activity, deter-
mines the ability ofCsA analogues to induce nephrotoxicity.
Discussion
In this report we analyze 61 CsA analogues for their ability
to inhibit lymphocyte activation, to bind to ryclophilin, to
inhibit PPIase activity, and to induce renal pathology. The
central question addressed in these experiments concerns the
role of ryclophilin in mediating the immunosuppressive and
nephrotoxic mechanism(s) of action ofCsA. Since its iden-
tification by Handschumacher et al. (11) in 1984, ryclophilin
has been an attractive biochemical target as the transducer
of CsA'S action . In contrast to other molecules identified as
CsA receptors, such as calmodulin (43, 44) and the prolactin
receptor (45), several groups have demonstrated that only im-
munosuppressive CsA analogs can interact with ryclophilin
(11, 12) . While it is unclear how a protein as ubiquitous as
ryclophilin could mediate CsNs activity in a lymphocyte-
selective manner, the hypothesis favoring a critical role for
ryclophilin was strengthened by the discovery of an enzy-
matic activity for this protein (13, 14) . Another observation
further supporting this notion was the recent finding that
the major cytosolic receptor for another immunosuppressive
agent, FK-506, is also a PPIase (18, 19) . Despite this impres-
sive body of circumstantial evidence, experiments presented
in this paper lead us to conclude that the role of ryclophilin
in lymphocyte signal transduction remains uncertain .
As shown in previous studies (12), a good correlation was
observed between ryclophilin binding and immunosuppres-
sive activity for the vast majority of analogues analyzed . Com-
bined with the observation that the major intracellular
receptors for both CsA and FK-506 possess PPIase activity
(18, 19), the observed correlation suggests that ryclophilin,
or a closely related molecule, is involved in CsA'S immunosup-
pressive mechanism of action .
On the other hand, a number ofcompounds of distinct
structural classes (collectively designated as class IV com-
pounds) were found that could interact with ryclophilin but
were much less immunosuppressive than expected . In addi-
tion, McBm2t was immunosuppressive yet bound weakly to
ryclophilin and lacked significant PPIase inhibitory activity.
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The inability of the class IV analogs to inhibit lymphocyte
activation could not be explained by their failure to enter the
cell and bind to cyclophilin under the conditions used in the
cellular assays. Furthermore, at concentrations of McAla-6
that should have occupied most the intracellular cyclophilin,
this analogue could not be demonstrated to act as an antagonist
of CsA's immunosuppressive activity. Thus, the paradox
created by the class IV compounds suggests that the rela-
tionship, if any, between cyclophilin binding and immunosup-
pressive activity is not a direct one.
The McAla-6 and McBm2t analogues inhibit cyclophilin's
PPIase activity in proportion to their ability to displace
[3H]dihydro cyclosporin from the molecule and not in agree-
ment with their immunosuppressive activity. This finding
clouds the hypothesis that PPIase has a direct function in lym-
phocyte signal transduction. One must consider, however,
that the PPIase assay currently used employs a synthetic
tetrapeptide as substrate whichmay not accurately reflect the
more complex interactions between cyclophilin and polypep-
tide substrates within the cell . We and others have specu-
lated that PPIases could be involved in signal transduction
pathways through alteration ofthe conformation of transcrip-
tion factors, ion channels, or protein kinases. Although the
fact that the FK-506 binding protein, FKBP, also is a PPIase
(inhibitable by its immunosuppressive ligand) (18, 19) must
be viewed as more than a fortuitous coincidence, the evidence
points to amuch more subtle/complex role for these enzymes
than previously hypothesized .
What alternatives to a central role for ryclophilin might
be envisioned? First, other proteins, perhaps evolutionarily
related to cyclophilin, may be involved in C&A's mechanism
of action . Southern blotting has revealed a number of genes
that crosshybridize with a ryclophilin cDNA probe (46) . A
gene product genetically related to ryclophilin and perhaps
expressed in a lymphocyte-specific fashion could account for
the correlation between immunosuppression and ryclophilin
binding and for the selectivity ofCsA for lymphocyte signal
transduction pathways . Such a protein would be expected to
bind McBm2t but fail to interact with McAla-6 . A second
possibility might be that binding to ryclophilin and PPIase
inhibition is necessary but not sufficient for immunosuppres-
sion . For example, cyclophilin, through its PPIase activity,
may alter the conformation ofCsA in such a way that it can
now bind to a second acceptor molecule, which actually
mediates C&A's immunosuppressive effect . Recently, Fesik et
al . (47) have shown by isotope filteredNMR methods that
CsA does adopt a new conformation when it is bound to
human or bovine ryclophilin . The bound conformation of
CsA contains a trans amide bond between amino acid residues
McLeu-9/MeLeu-10 instead of the cis amide bond present in
the solution and X-ray conformations. It is possible that the
class III analogue McBm2t is able to bind efficiently to the
immunosuppressive receptor without assistance from ry-
clophilin . In contrast, an analogue such as McAla-6 might
interact appropriately with ryclophilin but fail to bind to the
acceptor protein . Third, ryclophilin, in addition to its role
as a PPIase involved in protein folding, may be a subunit ofa larger holoenzyme complex, the function of which is im-
portant in lymphocyte activation but only distantly related
to itsknown PPIase activity. Disulfide isomerase, anenzyme
important in protein folding, has been documented to func-
tion as a subunit in enzymatic activities unrelated to its house-
keeping role (48) .
The observation that induction of nephrotoxicity corre-
lates with the immunosuppressive activity of the CsA ana-
logues tested has important clinical and mechanistic implica-
tions. The results suggest that it will be difficult to discover
nonnephrotoxic CsA analogues that retain significant im-
munosuppressive activity. Segregation of the two activities
may still be possible by altering a compound's distribution
or metabolism . From a mechanistic perspective, the data imply
that nephrotoxicity is due to similarities in signal transduc-
tion pathways between the lymphocyte and the cells involved
in the renal pathophysiology . The principal side effect ofCsA
is clearly not due to inhibition of PPIase activity in other
cell types. The question ofwhether identical molecules mediate
nephrotoxicity and immunosuppression or whether the side
effects are due to crosstalk between related pathways remains
to be determined .
The remarkable similarities between CsA and FK-506 with
respect to their cellular and biochemical mechanism of ac-
tion provide an important opportunity to better understand
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how these molecules interfere with lymphocyte activation
and, in this way, gain insight into the biochemical processes
that mediate signal transduction . BothCsA and FK-506 selec-
tively inhibit lymphocyte activation pathways that are as-
sociated with a rise in intracellular.calcium (6-10) . The events
inhibited by these agents appear to be distal to membrane-
associated processes, such as calcium flux, phosphoinositide
generation, and phosphorylation events (49, 50), but prox-
imal to the transcriptional events regulating lymphokine gene
expression . Identification of the biochemical steps critical to
the action of these immunosuppressants should take into ac-
count these observations . The studies described in this re-
port underscore the complexity of these intermediate steps
in the transduction process . Experiments with FKBP sug-
gest a level of complexity similar to that observed with cy-
clophilin. In particular, rapamycin, a molecule structurally
related to FK-506, binds to FKBP and inhibits its PPIase ac-
tivity, but does not inhibit IIr2 gene transcription and, in-
deed, acts as an antagonist of FK-506's immunosuppressive
activity (reference 32 and J . Siekierka, R. Harrison, C . S .
Lin, S. H. Y Hung, andN.H . Sigal, manuscript submitted
for publication) . Although we do not, as yet, have a sufficient
understanding to reconcile such observations, it is hoped that
the insights gained will lead to the discovery and develop-
ment ofmore potent and selective immunosuppressive agents .
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